|Description||CP-220629, a Pyrazolopyridin derivative, has been found to be a Type 4 cyclic nucleotide phosphodiesterase inhibitor that was once studied as an anti-inflammatory as well as antiasthmatic agent.|
|Synonyms||UNII-BAV9N49AFE; CP-220629; BAV9N49AFE; SCHEMBL84865; CHEMBL75819; 1-cyclopentyl-3-ethyl-6-(2-methylphenyl)-4,5-dihydropyrazolo[3,4-c]pyridin-7-one|
|Storage||Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).|
|Quality Standard||In-house standard|
AN3199, a PDE4 inhibitor, was once studied as an anti-inflammatory agent. IC50: 94.5 nM
MK-0359 is a selective and potent oral PDE4 inhibitor with in vivoefficacy in animal models of asthma and cognition.
MK0873 is a phosphodiesterase 4 (PDE4) inhibitor. It has shown as an innovative tool to design topical formulation to achieve desired pharmacokinetics in humans...
CP-220629, a Pyrazolopyridin derivative, has been found to be a Type 4 cyclic nucleotide phosphodiesterase inhibitor that was once studied as an anti-inflammato...
Zardaverine is a newly developed dual-selective PDE3/4 inhibitor with IC50 values of 0.5 μM and 0.8 μM respectively.
Ronomilast is type 4 cyclic nucleotide phosphodiesterase inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).
Apremilast (CC-10004)is an orally available small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast specifically inhibits PDE4 and inhibits spontaneo...
GSK256066 2,2,2-trifluoroacetic acid
GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold...
Crisaborole is a novel PDE-4 inhibitor used as a nonsteroidal topical medication for the treatment of mild-to-moderate atopic dermatitis (eczema). Crisaborole s...
Roflumilast has antiinflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such ...
CI-1044, a selective PDE4 inhibitor, inhibits in vitro LPS-induced TNF-alpha release in whole blood from COPD patients better than rolipram and cilomilast and s...
NVP-ABE171 is a potent and novel phosphodiesterase 4 inhibitor with anti-inflammatory activities inhibited the activity of phosphodiesterase 4A, 4B, 4C, and 4D ...
GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selec...
GSK-356278 is a selective Type 4 cyclic nucleotide phosphodiesterase inhibitor. It shows anxiolytic and cognition-enhancing effects and it has the ability to el...
S-(+)-Rolipram inhibits human monocyte cyclic AMP-specific PDE4 with IC50 of 0.75 μM, has anti-inflammatory and anti-depressant activity in the central nervous ...
L-869298 is a high potent and selective PDE4 inhibitor, acts as a Type 4 cyclic nucleotide phosphodiesterase inhibitor.
Tilivapram, a pyridine derivative, has been found to be a phosphodiesterase IV inhibitor that could probably be used in studying its bioactivities in sorts of a...
CP-671305 is a potent and selective inhibitor of PDE4.
Oglemilast is a potent PDE4 inhibitor and under clinical studies in the treatment of allergen-induced asthma.
Rolipram is a selective PDE4-inhibitor and an anti-inflammatory agent.